In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist.

@article{Zhang2002InVM,
  title={In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist.},
  author={Qiang Zhang and Peng Ma and Marcus Iszard and Richard B. Cole and Weiqun Wang and Guangdi Wang},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2002},
  volume={30 10},
  pages={
          1077-86
        }
}
R(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2, 3-de]1,4-benzoxa zinyl]-(1-naphthalenyl methanone mesylate (WIN55212-2) is a potent cannabinoid receptor agonist that has been found to exhibit antinociceptive activity and to inhibit brain cyclooxygenase. The metabolism of WIN55212-2 has not been reported, and it is unknown whether its metabolites retain any agonist properties. In this study, in vitro metabolism of WIN55212-2 in rat liver microsome was investigated. The metabolic… 

Figures and Tables from this paper

In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)
TLDR
It was concluded that all metabolites formed in vivo were excreted conjugated as glucuronide or sulfate, with conjugation rates above 50 %.
Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968).
TLDR
Synthetic standards were synthesized in order to gain insight into regio- and enantioselectivity of the metabolic oxidation of 1 and to verify the structures of four metabolites that were proposed earlier in a clinical ADME study.
Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS.
TLDR
In conclusion, WIN 55,212-2 was extensively metabolized in human liver microsomes incubations and the calculated hepatic clearance was comparably high, indicating a fast and nearly complete metabolism in vivo, in line with previous findings on other synthetic cannabinoids.
IN VITRO METABOLISM OF DIARYLPYRAZOLES, A NOVEL GROUP OF CANNABINOID RECEPTOR LIGANDS
TLDR
A study of the in vitro metabolisms of three diarylpyrazole analogs, SR141716A, AM251, and AM281, in rat liver microsomes, using high-performance liquid chromatography with UV and mass spectrometry detectors finds all identified metabolites are characterized by structural modifications on the terminal group of the 3-substituent.
Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
TLDR
Test the hypothesis that JWH-018 and its fluorinated counterpart AM2201 are subject to cytochrome P450 (P450)-mediated oxidation, forming potent hydroxylated metabolites that retain significant affinity and activity at the cannabinoid 1 (CB1) receptor.
Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate
TLDR
Oxidation of the naphthalene moiety was demonstrated to be the cause of the high in vivo clearance of compound A and the potential for bioactivation of this group was flagged.
In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200.
TLDR
The metabolite formed by consecutive morpholine cleavage and oxidation of the remaining side chain to a carboxylic group was detected in the highest amounts with the longest detection time and is the best candidate metabolite to detect JWH-200 abuse in urine.
Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS
The in vitro microsomal metabolism of JWH-015, a ligand that exhibits a high binding affinity at the peripheral cannabinoid receptor CB2, has been studied. A total of 22 metabolites were identified
In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB(2)) in rat liver microsomes.
...
1
2
3
4
...

References

SHOWING 1-10 OF 18 REFERENCES
Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2.
Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor.
TLDR
Binding studies with this ligand have helped demonstrate that the (aminoalkyl)indole binding site is functionally equivalent with the CP-55,940 cannabinoid binding site, representing a new class of cannabinoid receptor agonists.
Metabolic disposition of a monoterpene ketone, piperitenone, in rats: evidence for the formation of a known toxin, p-cresol.
TLDR
A probable mechanism for the formation of p-cresol from piperitenone (I) via the intermediacy of metabolite III has been proposed.
Antinociceptive (aminoalkyl)indoles.
TLDR
The low eudismic ratios of the alpha-methyl derivatives and the observation that the side chain may be extended by three methylene groups without significant loss of PG inhibitory potency suggests that this class of inhibitors bound less strongly and less selectively to the active site of PG synthetase than do the arylacetic acids.
Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids.
TLDR
The effect of cannabinoids on AAI binding was consistent with competitive inhibition and suggests that AAI activity may be mediated in whole or in part by interaction with cannabinoid receptors, appearing to represent a structurally novel class of compounds with which to study cannabinoid receptors.
Absorption, Distribution, and Biotransformation of the Cannabinoids
TLDR
This paper describes the occurrence, properties, distribution, metabolism, and excretion of the cannabinoids, the major ones being the pharmacologically active Δ9-tetrahydrocannabinol, its biosynthetic precursor, cannabidiol (CBD), and the degradation product, cannabinol (CBN).
Regional haemodynamic responses to the cannabinoid agonist, WIN 55212‐2, in conscious, normotensive rats, and in hypertensive, transgenic rats
TLDR
The results indicate that the predominant cardiovascular effects of WIN 55212‐2 in conscious HSD and TG rats can be attributed largely to indirect, pentolinium‐sensitive mechanisms, which appear to differ little in the normotensive and hypertensive state, at least in conscious animals.
Aminoalkylindoles: actions on specific G-protein-linked receptors.
TLDR
The results suggest that AAIs bind to specific receptors which are coupled through G-proteins to inhibit adenylyl cyclase, which is similar to how serotonin binds to guanine nucleotides in humans.
Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2.
TLDR
It is demonstrated that like natural cannabinoids, WIN55212-2 also reduces intraocular pressure, and the effects are mediated at least in part by the CB1 cannabinoid receptors in the eye.
...
1
2
...